Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01925469 · ClinicalTrials.gov registry record · Phase 4

Benzocaine Versus Placebo Spray for Pain Relief at Hysterosalpingogram

A Phase 4 study of Analgesia and Pain Relief, sponsored by University of Pennsylvania.

Completed
Registry status
Phase 4
Development phase
30
Enrollment target
1
Study location

NCT01925469: Completed Phase 4 study of Analgesia and Pain Relief, sponsored by University of Pennsylvania.

NCT01925469 is a Phase 4 study of Analgesia and Pain Relief that has completed, run by University of Pennsylvania. The registered enrollment target is 30 participants, below the 91-participant average among 19 other Analgesia trials with a reported enrollment target (67% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01925469, a Phase 4 study of Analgesia and Pain Relief, has completed, sponsored by University of Pennsylvania.

COMPLETED
Registry status
Phase 4
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

The objective of this study is to assess the utility of benzocaine spray versus a placebo spray in alleviating pain during and after hysterosalpingogram (HSG).

Primary Outcome

The primary outcome is the difference in pain score using a validated visual analog scale before the procedure, which is designated as the pre-procedure (or baseline) pain score to the maximum pain during procedure (designated as time 0) These two pain scores will be subtracted and the change in pain score will be reported. The validated visual analog scale allows patients to report pain on a scale of 0 to 100 mm long. At the beginning and at the end, there are two descriptors representing extre

Conditions Studied

Interventions

  • DRUG Benzocaine
  • DRUG Saline spray

Study Locations (1)

Pennsylvania

  • University of Pennsylvania - Philadelphia

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2011-12
Est. Completion 2012-04
Phase Phase 4
University of Pennsylvania

1,423 total trials

What the finished NCT01925469 record still lists

NCT01925469 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 91-participant average among 19 other Analgesia trials with a reported enrollment target (67% lower).

The record links to 2 conditions, with Analgesia appearing as the primary indexed condition, and to 2 interventions - of which Benzocaine is the first listed.

NCT01925469 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT01925469 about?

NCT01925469 is a clinical study titled "Benzocaine Versus Placebo Spray for Pain Relief at Hysterosalpingogram". The objective of this study is to assess the utility of benzocaine spray versus a placebo spray in alleviating pain during and after hysterosalpingogram (HSG).

What is the current status of trial NCT01925469?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2011-12. Estimated completion is 2012-04.

What conditions does trial NCT01925469 study?

This clinical trial studies the following conditions: Analgesia, Pain Relief.

What interventions are being tested in trial NCT01925469?

The interventions under investigation include: Benzocaine (DRUG), Saline spray (DRUG).

Who is sponsoring clinical trial NCT01925469?

This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01925469 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Analgesia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01925469's enrollment target sits among peer trials

30 19th of 19 higher than 1 of 19 other Analgesia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Analgesia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01925469, the US trial registry maintained by the National Library of Medicine. NCT01925469 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.